Bristol Myers Squibb (NYSE:BMY) Issues FY 2026 Earnings Guidance

Bristol Myers Squibb (NYSE:BMY) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.050-6.350 for the period, compared to the consensus estimate of 6.040. The company issued revenue guidance of $46.0 billion-$47.5 billion, compared to the consensus revenue estimate of $44.2 billion.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $61.99 on Friday. Bristol Myers Squibb has a one year low of $42.52 and a one year high of $63.33. The stock has a 50-day moving average of $54.34 and a 200 day moving average of $49.03. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The company has a market capitalization of $126.20 billion, a price-to-earnings ratio of 17.97, a PEG ratio of 0.18 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 70.30%. The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the prior year, the company posted $1.67 EPS. Bristol Myers Squibb’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts forecast that Bristol Myers Squibb will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were paid a dividend of $0.63 per share. The ex-dividend date was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 85.14%.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of research reports. Citigroup raised their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research note on Friday. Piper Sandler reissued an “overweight” rating and issued a $66.00 target price (up previously from $62.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 28th. UBS Group upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price target for the company from $46.00 to $65.00 in a research note on Wednesday, January 7th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Eight equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $59.20.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q4 revenue beat and growth portfolio momentum — BMY reported $12.5B in Q4 revenue with growth in new products (immuno‑oncology) helping offset legacy declines; investors view the topline beat as validating the company’s transition. Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
• Positive Sentiment: Upside FY‑2026 guidance — management set FY‑2026 EPS of $6.05–$6.35 and revenue guidance of $46.0–$47.5B, both above consensus, which markets are treating as a material bullish catalyst for forward earnings and cash flow expectations. Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off
• Positive Sentiment: Management and pipeline commentary — CEO Chris Boerner highlighted the strongest pipeline in a decade and called out new growth engines, supporting investor confidence in sustained medium‑term revenue growth. Bristol Myers Squibb CEO: Richest product pipeline we’ve had in the last decade
• Positive Sentiment: Street reaction — Citigroup raised its price target from $60 to $64 (maintaining a neutral rating), signalling modest analyst support for upside after the print and guidance. Tickerreport: Citigroup raises target
• Neutral Sentiment: Dividend/total-return thesis discussed — commentary (Seeking Alpha) frames BMY as a dividend income play with hidden upside from pipeline and buybacks; relevant for income-oriented investors but less immediate as a price catalyst. Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026
• Negative Sentiment: EPS mix and legacy headwinds — non‑GAAP EPS dynamics and year‑over‑year decline in EPS (and some legacy drug declines) remain a risk; some outlets note EPS was below certain Street figures and that company sales may decline in 2026 before new-product gains fully offset legacy erosion. MarketBeat: Earnings and call materials
• Negative Sentiment: Some analysts/publication notes that overall sales could decline in 2026 — this has been flagged as a medium‑term headwind that could pressure consensus if new-product uptake lags expectations. MSN: Bristol Myers expects sales to decline this year

Hedge Funds Weigh In On Bristol Myers Squibb

A number of hedge funds have recently modified their holdings of the company. Brighton Jones LLC boosted its stake in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. Sivia Capital Partners LLC boosted its stake in Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 2,786 shares during the period. United Bank grew its holdings in Bristol Myers Squibb by 15.0% during the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after buying an additional 3,277 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $221,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $405,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.